Clinical Trials
45 trialsContinuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
National Institutes of Health Clinical Center (CC)
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
City of Hope Medical Center
A Phase â… Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
SPARTACUS
Icahn School of Medicine at Mount Sinai
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
Institute of Hematology & Blood Diseases Hospital, China
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Arovella Therapeutics Ltd
SOUNDTRACK-C1
AstraZeneca
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Massachusetts General Hospital
TPG
Brown University
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Massachusetts General Hospital
Archonc-001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
CALySSEY
Baylor College of Medicine
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
ACITAC-001
Instituto Distrital de Ciencia, BiotecnologÃa e Innovación en Salud - IDCBIS
CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma
Tianjin First Central Hospital
Diagnostic Value and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy Versus Transbronchial Needle Aspiration in the Diagnosis of Lymphoma: a Randomized Controlled Trial
China-Japan Friendship Hospital
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy
Zhujiang Hospital
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
Affiliated Hospital of Jiangsu University
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group
PEPOH
University of Salamanca
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
Hebei Senlang Biotechnology Inc., Ltd.
ADAPT-MCL
Tianjin Medical University Cancer Institute and Hospital
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Guangzhou Bio-gene Technology Co., Ltd
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
CAR-T，MTD
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
PACMAN
Princess Maxima Center for Pediatric Oncology
CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia
Tianjin First Central Hospital
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer
Ciusss de L'Est de l'Île de Montréal
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
Fox Chase Cancer Center
CAR-T Therapy
Zhengzhou University
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Ruijin Hospital
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Sun Yat-sen University
RAT-HEMATO
University Hospital, Angers
Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
Salarius Pharmaceuticals, LLC
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital
Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
KCAT19
University College, London
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.